<DOC>
	<DOC>NCT00004380</DOC>
	<brief_summary>OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma). II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and cultured from skin biopsies.</brief_summary>
	<brief_title>Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a compassionate use study. The patient is treated with subcutaneous injections of recombinant relaxin for approximately 12 months. If clinically indicated, therapy may be extended.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma, Systemic</mesh_term>
	<mesh_term>Scleroderma, Diffuse</mesh_term>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Progressive systemic sclerosis (scleroderma) No pregnant or nursing women</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>arthritis &amp; connective tissue diseases</keyword>
	<keyword>rare disease</keyword>
	<keyword>systemic sclerosis</keyword>
</DOC>